The stock price of BioNTech SE ADR (NASDAQ: BNTX) has dropped by -0.07 compared to previous close of 92.08. Despite this, the company has seen a fall of -2.91% in its stock price over the last five trading days. youtube.com reported 2025-05-07 that CNBC’s Angelica Peebles joins ‘Squawk on the Street’ to discuss how the biotech and pharma industry is reacting to a new FDA chief of vaccines appointed by President Trump.
Is It Worth Investing in BioNTech SE ADR (NASDAQ: BNTX) Right Now?
The stock has a 36-month beta value of 1.28. Opinions on the stock are mixed, with 13 analysts rating it as a “buy,” 4 as “overweight,” 5 as “hold,” and 0 as “sell.”
The public float for BNTX is 236.70M, and at present, short sellers hold a 1.96% of that float. On May 15, 2025, the average trading volume of BNTX was 1.12M shares.
BNTX’s Market Performance
BNTX stock saw a decrease of -2.91% in the past week, with a monthly decline of -7.05% and a quarterly a decrease of -25.05%. The volatility ratio for the week is 3.76%, and the volatility levels for the last 30 days are 5.70% for BioNTech SE ADR (BNTX). The simple moving average for the last 20 days is -8.63% for BNTX’s stock, with a simple moving average of -13.87% for the last 200 days.
Analysts’ Opinion of BNTX
Many brokerage firms have already submitted their reports for BNTX stocks, with Citigroup repeating the rating for BNTX by listing it as a “Buy.” The predicted price for BNTX in the upcoming period, according to Citigroup is $145 based on the research report published on March 13, 2025 of the current year 2025.
Truist, on the other hand, stated in their research note that they expect to see BNTX reach a price target of $172. The rating they have provided for BNTX stocks is “Buy” according to the report published on January 10th, 2025.
Wells Fargo gave a rating of “Overweight” to BNTX, setting the target price at $170 in the report published on December 11th of the previous year.
BNTX Trading at -6.50% from the 50-Day Moving Average
After a stumble in the market that brought BNTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -30.02% of loss for the given period.
Volatility was left at 5.70%, however, over the last 30 days, the volatility rate increased by 3.76%, as shares sank -7.34% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -20.68% lower at present.
During the last 5 trading sessions, BNTX fell by -3.95%, which changed the moving average for the period of 200-days by +5.11% in comparison to the 20-day moving average, which settled at $100.66. In addition, BioNTech SE ADR saw -19.25% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BNTX starting from Jeggle Helmut Wolfgang, who proposed sale 150,000 shares at the price of $94.74 back on May 07 ’25. After this action, Jeggle Helmut Wolfgang now owns shares of BioNTech SE ADR, valued at $14,211,000 using the latest closing price.
Richardson Ryan, the Officer of BioNTech SE ADR, proposed sale 26,500 shares at $114.00 during a trade that took place back on Feb 27 ’25, which means that Richardson Ryan is holding shares at $3,021,000 based on the most recent closing price.
Stock Fundamentals for BNTX
Current profitability levels for the company are sitting at:
- -0.39 for the present operating margin
- 0.8 for the gross margin
The net margin for BioNTech SE ADR stands at -0.25. The total capital return value is set at -0.05. Equity return is now at value -3.87, with -3.46 for asset returns.
Based on BioNTech SE ADR (BNTX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at 0.95. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -52.93.
Currently, EBITDA for the company is -367.1 million with net debt to EBITDA at 27.09. When we switch over and look at the enterprise to sales, we see a ratio of 3.74. The receivables turnover for the company is 1.8for trailing twelve months and the total asset turnover is 0.12. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.18.
Conclusion
To sum up, BioNTech SE ADR (BNTX) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
